Choroidal Neovascularization Market - 2024-2031
The Choroidal Neovascularization Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Choroidal Neovascularization Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
Both primary and secondary data sources have been used in the global Choroidal Neovascularization Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
A Choroidal Neovascularization Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
- Intravitreal*
- Intravenous
- Malignant Myopia Degeneration*
- Extreme Myopia
- Age-Related Developments
- Photodynamic Therapy*
- Verteporfin (Visudyne)
- Anti-VEGF therapy
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- Aflibercept intravitreal (Eylea)
- Pegaptanib (Macugen)
- Brolucizumab intravitreal
- Others
- Treatment Sales*
- Hospitals
- Others
- Distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Choroidal Neovascularization Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Product Type
3.2. Market Snippet By Application
3.3. Market Snippet By Treatment Type
3.4. Market Snippet by Treatment Sales
3.5. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of age related macular degeneration
4.1.1.2. Driver
4.1.2. Restraints:
4.1.2.1. Lack of awareness among people about different types of eye diseases.
4.1.2.2. Restraint
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Intravitreal*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Intravenous
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Malignant Myopia Degeneration*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Extreme Myopia
8.4. Age-Related Developments
9. BY TREATMENT TYPE
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.1.2. Market Attractiveness Index, By Treatment Type Segment
9.2. Photodynamic Therapy*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.2.3. Verteporfin (Visudyne)
9.3. Anti-VEGF therapy
9.3.1. Ranibizumab (Lucentis)
9.3.2. Bevacizumab (Avastin)
9.3.3. Aflibercept intravitreal (Eylea)
9.3.4. Pegaptanib (Macugen)
9.3.5. Brolucizumab intravitreal
9.4. Others
10. BY TREATMENT SALES
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
10.1.2. Market Attractiveness Index, By Treatment Sales Segment
10.2. Treatment Sales*
10.2.1.1. Introduction
10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.2.2. Hospitals
10.2.3. Others
10.3. Distribution channel
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
11. BY REGION
11.1. Introduction
11.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. U.S.
11.4.7.2. Canada
11.4.7.3. Mexico
11.5. Europe
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. Germany
11.5.7.2. U.K.
11.5.7.3. France
11.5.7.4. Italy
11.5.7.5. Spain
11.5.7.6. Rest of Europe
11.6. South America
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.6.7.1. Brazil
11.6.7.2. Argentina
11.6.7.3. Rest of South America
11.7. Asia Pacific
11.7.1. Introduction
11.7.2. Key Region-Specific Dynamics
11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.7.7.1. China
11.7.7.2. India
11.7.7.3. Japan
11.7.7.4. Australia
11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
11.8.1. Introduction
11.8.2. Key Region-Specific Dynamics
11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. Key Companies to Watch
13. COMPANY PROFILES
13.1. Bayer AG*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Novartis AG
13.3. Bausch Health Companies Inc
13.4. Gilead Sciences Inc
13.5. F.Hoffmann –La Roche AG
13.6. MaaT Pharma
13.7. Pfizer Inc
13.8. Quark Pharmaceuticals Inc
13.9. Regeneron Pharmaceuticals Inc
13.10. Suzuken Co.Ltd(*IST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Product Type
3.2. Market Snippet By Application
3.3. Market Snippet By Treatment Type
3.4. Market Snippet by Treatment Sales
3.5. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of age related macular degeneration
4.1.1.2. Driver
4.1.2. Restraints:
4.1.2.1. Lack of awareness among people about different types of eye diseases.
4.1.2.2. Restraint
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Intravitreal*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Intravenous
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Malignant Myopia Degeneration*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Extreme Myopia
8.4. Age-Related Developments
9. BY TREATMENT TYPE
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.1.2. Market Attractiveness Index, By Treatment Type Segment
9.2. Photodynamic Therapy*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.2.3. Verteporfin (Visudyne)
9.3. Anti-VEGF therapy
9.3.1. Ranibizumab (Lucentis)
9.3.2. Bevacizumab (Avastin)
9.3.3. Aflibercept intravitreal (Eylea)
9.3.4. Pegaptanib (Macugen)
9.3.5. Brolucizumab intravitreal
9.4. Others
10. BY TREATMENT SALES
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
10.1.2. Market Attractiveness Index, By Treatment Sales Segment
10.2. Treatment Sales*
10.2.1.1. Introduction
10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.2.2. Hospitals
10.2.3. Others
10.3. Distribution channel
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
11. BY REGION
11.1. Introduction
11.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. U.S.
11.4.7.2. Canada
11.4.7.3. Mexico
11.5. Europe
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. Germany
11.5.7.2. U.K.
11.5.7.3. France
11.5.7.4. Italy
11.5.7.5. Spain
11.5.7.6. Rest of Europe
11.6. South America
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.6.7.1. Brazil
11.6.7.2. Argentina
11.6.7.3. Rest of South America
11.7. Asia Pacific
11.7.1. Introduction
11.7.2. Key Region-Specific Dynamics
11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.7.7.1. China
11.7.7.2. India
11.7.7.3. Japan
11.7.7.4. Australia
11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
11.8.1. Introduction
11.8.2. Key Region-Specific Dynamics
11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. Key Companies to Watch
13. COMPANY PROFILES
13.1. Bayer AG*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Novartis AG
13.3. Bausch Health Companies Inc
13.4. Gilead Sciences Inc
13.5. F.Hoffmann –La Roche AG
13.6. MaaT Pharma
13.7. Pfizer Inc
13.8. Quark Pharmaceuticals Inc
13.9. Regeneron Pharmaceuticals Inc
13.10. Suzuken Co.Ltd(*IST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us
